RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
RenovoRx reported Q2 revenue of $909,000, an increase of 61% sequentially and 115% year-over-year, driven by growing adoption of the RenovoCath device. Based on the strong first-half performance, the company raised its full-year 2026 revenue guidance to a range of $3.75 million to $4.25 million, up from the prior range of $3.0 million to $4.0 million. Operationally, the company expanded its active commercial cancer center customers to 21, a 30% increase from the prior quarter, and marked the first use of RenovoCath in a sarcoma patient. In a significant clinical milestone, the Phase III TIGeR-PaC trial reached full enrollment, with topline data expected in the second half of 2027.
Key figures
- Revenue
- 909000
- Guidance
- FY2026 revenue $3.75M to $4.25M, raised from $3.0M to $4.0M
- Revenue Yoy
- 115%
- Cash
- 9500000
- Net loss
- 2900000
- Gross margin
- 84%
- Active centers
- 21
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.